ETI
HZNP

Enterprise Trust & Investment’s Horizon Therapeutics Public Limited Company Ordinary Shares HZNP Stock Holding History

Enterprise Trust & Investment’s Portfolio HZNP Stock Details HZNP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		$5K Buy
+68
New +$6.44K ﹤0.01% 285

Other funds holding HZNP

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
PC
Paulson & Co New York $3.11B AUM 94.93% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Enterprise Trust & Investment's HZNP Position: Q2 2022 in Review

Enterprise Trust & Investment opened a new position in Horizon Therapeutics Public Limited Company Ordinary Shares (HZNP) in Q2 2022: 68 shares worth $5K. The stake represents ﹤0.01% of the portfolio and ranks #285 among its holdings.

616 funds tracked by Wall St. Rank hold HZNP as of Q2 2022.

  • Enterprise Trust & Investment held 68 shares of Horizon Therapeutics Public Limited Company Ordinary Shares worth $5K as of Q2 2022.
  • Horizon Therapeutics Public Limited Company Ordinary Shares was a new Enterprise Trust & Investment position in Q2 2022.
  • Horizon Therapeutics Public Limited Company Ordinary Shares made up ﹤0.01% of Enterprise Trust & Investment's portfolio in Q2 2022, its #285 holding.
  • 616 funds tracked by Wall St. Rank held Horizon Therapeutics Public Limited Company Ordinary Shares as of Q2 2022.

Based on Enterprise Trust & Investment's 13F filing for Q2 2022, filed 22 Jul 2022.